TY - JOUR
T1 - NMOSD acute attack
T2 - Understanding, treatment and innovative treatment prospect
AU - Ma, Xiaoyu
AU - Kermode, Allan G.
AU - Hu, Xueqiang
AU - Qiu, Wei
PY - 2020/11/15
Y1 - 2020/11/15
N2 - Neuromyelitis optica spectrum disorder (NMOSD) is a group of severe inflammatory demyelinating disorders of the central nervous system that involves the optic nerve and spinal cord. Currently the therapeutic options for an acute attack in NMOSD are limited and rarely characterized in clinical studies. This review discussed the overall characteristics of acute attack of NMOSD, related risk factor, prognosis and management. Considering the huge unmet needs and the emergence of new therapeutic targets, we also reviewed innovative treatments that might alleviate attack damage, along with the challenges to evaluate new drug for acute attack in NMOSD.
AB - Neuromyelitis optica spectrum disorder (NMOSD) is a group of severe inflammatory demyelinating disorders of the central nervous system that involves the optic nerve and spinal cord. Currently the therapeutic options for an acute attack in NMOSD are limited and rarely characterized in clinical studies. This review discussed the overall characteristics of acute attack of NMOSD, related risk factor, prognosis and management. Considering the huge unmet needs and the emergence of new therapeutic targets, we also reviewed innovative treatments that might alleviate attack damage, along with the challenges to evaluate new drug for acute attack in NMOSD.
KW - Acute attack
KW - Innovative treatment
KW - Neuromyelitis optica spectrum disorder
KW - Risk factor
KW - Severe attack
UR - http://www.scopus.com/inward/record.url?scp=85091638899&partnerID=8YFLogxK
U2 - 10.1016/j.jneuroim.2020.577387
DO - 10.1016/j.jneuroim.2020.577387
M3 - Review article
C2 - 32987231
AN - SCOPUS:85091638899
VL - 348
JO - Journal of Neuroimmunology
JF - Journal of Neuroimmunology
SN - 0165-5728
M1 - 577387
ER -